patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_750622 | REC_0007301 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 15.2 | 65 | female | 0 | 18 | 2 | 9 | osimertinib 80 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:58.643056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313395 | REC_0007302 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13.7 | 69 | female | 0 | 21 | 6.3 | 6 | osimertinib 80 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:58.643286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600242 | REC_0007303 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.9 | 74 | female | 1 | 24 | 6.4 | 6 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:58.643519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440435 | REC_0007304 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 27 | 13.8 | 67 | male | 1 | 10 | 4.7 | 0 | alectinib 600 mg BID | 34.7 | false | MSS | 2026-03-15T05:35:58.643755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442557 | REC_0007305 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 7.5 | 70 | male | 2 | 17 | 4 | 3 | osimertinib 80 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:58.643986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227074 | REC_0007306 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 16.3 | 78 | female | 3 | 25 | 5.2 | 2 | sotorasib 960 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:58.644246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826642 | REC_0007307 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 2.8 | 81 | female | 2 | 10 | 6.2 | 5 | pembrolizumab 200 mg q3w | 12 | true | MSS | 2026-03-15T05:35:58.644526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738456 | REC_0007308 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 13 | 3.5 | 77 | female | 1 | 13 | 6.4 | 7 | pembrolizumab 200 mg q3w | 5.7 | false | MSS | 2026-03-15T05:35:58.644757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767780 | REC_0007309 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 11.1 | 58 | male | 0 | 5 | 4.1 | 2 | pembrolizumab 200 mg q3w | 18.8 | false | MSI-H | 2026-03-15T05:35:58.644994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361206 | REC_0007310 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.9 | 60 | female | 1 | 25 | 7.4 | 7 | sotorasib 960 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:58.645229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506071 | REC_0007311 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 3.2 | 62 | male | 0 | 14 | 4.6 | 7 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:35:58.645466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647943 | REC_0007312 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.8 | 67 | female | 0 | 10 | 4.9 | 6 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:58.645700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102000 | REC_0007313 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 7.4 | 58 | male | 1 | 10 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.8 | false | MSS | 2026-03-15T05:35:58.645931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343506 | REC_0007314 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 5 | 71 | female | 3 | 64 | 7.7 | 1 | pembrolizumab 200 mg q3w | 20.4 | false | MSS | 2026-03-15T05:35:58.646162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442338 | REC_0007315 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 14.7 | 69 | male | 0 | 14 | 4.1 | 4 | pembrolizumab 200 mg q3w | 13.7 | true | MSS | 2026-03-15T05:35:58.646400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122345 | REC_0007316 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 7 | 66 | female | 0 | 12 | 4.8 | 6 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:58.646626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191130 | REC_0007317 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.8 | 57 | female | 1 | 17 | 6.2 | 5 | alectinib 600 mg BID | 7.2 | true | MSI-H | 2026-03-15T05:35:58.646859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965102 | REC_0007318 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 24 | 7.3 | 75 | female | 0 | 5 | 8.1 | 0 | pembrolizumab 200 mg q3w | 27.7 | true | MSS | 2026-03-15T05:35:58.647089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492125 | REC_0007319 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 6.3 | 58 | male | 0 | 23 | 6.8 | 1 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:35:58.647320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975001 | REC_0007320 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 11.6 | 65 | female | 1 | 9 | 4.4 | 2 | entrectinib 600 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:58.647596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127374 | REC_0007321 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 2.2 | 75 | female | 2 | 10 | 8.1 | 1 | entrectinib 600 mg daily | 24.6 | true | MSS | 2026-03-15T05:35:58.647827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232023 | REC_0007322 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 6.8 | 65 | female | 1 | 19 | 5.2 | 6 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:35:58.648061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629262 | REC_0007323 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 15 | 70 | female | 2 | 12 | 5.9 | 5 | entrectinib 600 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:58.648430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275965 | REC_0007324 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 13.7 | 69 | female | 0 | 20 | 6.3 | 5 | sotorasib 960 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:35:58.648663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426389 | REC_0007325 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 9.5 | 64 | male | 1 | 15 | 4.2 | 3 | entrectinib 600 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:58.648897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298806 | REC_0007326 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.8 | 66 | female | 0 | 2 | 7.2 | 4 | alectinib 600 mg BID | 9.3 | true | MSS | 2026-03-15T05:35:58.649127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735774 | REC_0007327 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.3 | 63 | male | 0 | 12 | 4 | 2 | entrectinib 600 mg daily | 18.9 | true | MSI-H | 2026-03-15T05:35:58.649362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947784 | REC_0007328 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 9.2 | 72 | female | 2 | 13 | 5.1 | 6 | entrectinib 600 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:58.649592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108143 | REC_0007329 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12.3 | 62 | male | 0 | 12 | 8.2 | 2 | sotorasib 960 mg daily | 22.2 | false | MSS | 2026-03-15T05:35:58.649827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470945 | REC_0007330 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.6 | 65 | female | 1 | 17 | 5.4 | 8 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:58.650058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873907 | REC_0007331 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 12.6 | 81 | female | 1 | 18 | 4.2 | 8 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:35:58.650293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546526 | REC_0007332 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.7 | 65 | female | 1 | 13 | 7.3 | 3 | alectinib 600 mg BID | 7 | false | MSS | 2026-03-15T05:35:58.650529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760611 | REC_0007333 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 7.7 | 52 | female | 0 | 8 | 5.5 | 4 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:58.650810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418426 | REC_0007334 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 15.1 | 53 | male | 0 | 8 | 6.5 | 4 | pembrolizumab 200 mg q3w | 11.4 | true | MSI-H | 2026-03-15T05:35:58.651048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998856 | REC_0007335 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 12.4 | 64 | female | 0 | 15 | 6.2 | 6 | sotorasib 960 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:58.651290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696976 | REC_0007336 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 39 | 10.8 | 69 | female | 1 | 25 | 6.4 | 1 | osimertinib 80 mg daily | 27.4 | false | MSI-H | 2026-03-15T05:35:58.651527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785484 | REC_0007337 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.1 | 61 | male | 0 | 20 | 4.5 | 5 | alectinib 600 mg BID | 8.7 | false | MSI-H | 2026-03-15T05:35:58.651763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312771 | REC_0007338 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 11.7 | 56 | female | 1 | 16 | 5 | 4 | osimertinib 80 mg daily | 5 | true | MSI-H | 2026-03-15T05:35:58.651995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542100 | REC_0007339 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 17.6 | 61 | female | 1 | 15 | 3.8 | 5 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:58.652262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686648 | REC_0007340 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.4 | 75 | male | 2 | 69 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:35:58.652510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604940 | REC_0007341 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 6.1 | 72 | male | 1 | 17 | 4.6 | 2 | pembrolizumab 200 mg q3w | 21.8 | false | MSS | 2026-03-15T05:35:58.652744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571576 | REC_0007342 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.4 | 73 | male | 2 | 13 | 6.5 | 7 | sotorasib 960 mg daily | 14 | false | MSS | 2026-03-15T05:35:58.652980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781936 | REC_0007343 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 7.7 | 61 | male | 0 | 17 | 5.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:58.653212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345544 | REC_0007344 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.5 | 64 | male | 0 | 19 | 7.2 | 1 | alectinib 600 mg BID | 14.4 | false | MSS | 2026-03-15T05:35:58.653450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996640 | REC_0007345 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 35 | 8.1 | 46 | male | 0 | 20 | 6.4 | 7 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:58.653684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654714 | REC_0007346 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5 | 77 | male | 1 | 43 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:35:58.653959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481327 | REC_0007347 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.4 | 66 | male | 1 | 36 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.8 | true | MSS | 2026-03-15T05:35:58.654193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181373 | REC_0007348 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.8 | 59 | male | 0 | 0 | 6.3 | 3 | entrectinib 600 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:58.654428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507619 | REC_0007349 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13.9 | 65 | male | 0 | 22 | 5.6 | 8 | sotorasib 960 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:35:58.654665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959024 | REC_0007350 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 11.8 | 62 | female | 1 | 18 | 5.8 | 1 | sotorasib 960 mg daily | 21.8 | false | MSI-H | 2026-03-15T05:35:58.654898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763228 | REC_0007351 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 9.2 | 69 | female | 0 | 6 | 5.7 | 2 | sotorasib 960 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:58.655130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341040 | REC_0007352 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.4 | 67 | female | 1 | 15 | 5.9 | 3 | sotorasib 960 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:58.655362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564117 | REC_0007353 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 4.1 | 70 | female | 2 | 36 | 7.4 | 1 | pembrolizumab 200 mg q3w | 11.2 | true | MSS | 2026-03-15T05:35:58.655591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529148 | REC_0007354 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 16.1 | 62 | female | 0 | 20 | 4.9 | 1 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:58.655826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531179 | REC_0007355 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 9.3 | 62 | male | 0 | 37 | 8.6 | 1 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:35:58.656057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194565 | REC_0007356 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 5.4 | 71 | female | 1 | 6 | 5.8 | 1 | osimertinib 80 mg daily | 16.7 | true | MSS | 2026-03-15T05:35:58.656395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971262 | REC_0007357 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 15 | 73 | female | 0 | 3 | 6.1 | 2 | osimertinib 80 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:58.656627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136374 | REC_0007358 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8.8 | 76 | male | 2 | 44 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.5 | false | MSS | 2026-03-15T05:35:58.656860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939431 | REC_0007359 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.5 | 63 | female | 0 | 12 | 3.8 | 5 | alectinib 600 mg BID | 10.7 | false | MSS | 2026-03-15T05:35:58.657143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389236 | REC_0007360 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 3.7 | 72 | female | 2 | 4 | 7.7 | 1 | osimertinib 80 mg daily | 28.6 | false | MSS | 2026-03-15T05:35:58.657375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688374 | REC_0007361 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.7 | 74 | female | 0 | 6 | 6.1 | 2 | osimertinib 80 mg daily | 28.3 | false | MSS | 2026-03-15T05:35:58.657607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353666 | REC_0007362 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.3 | 81 | female | 1 | 16 | 5.1 | 1 | entrectinib 600 mg daily | 18 | false | MSS | 2026-03-15T05:35:58.657839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751483 | REC_0007363 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 4 | 77 | female | 1 | 12 | 7.9 | 7 | alectinib 600 mg BID | 9.2 | false | MSS | 2026-03-15T05:35:58.658067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501531 | REC_0007364 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.8 | 60 | female | 0 | 6 | 7.4 | 6 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:35:58.658297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825565 | REC_0007365 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 15.6 | 69 | female | 1 | 6 | 7.3 | 2 | osimertinib 80 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:58.658529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920137 | REC_0007366 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.5 | 88 | female | 0 | 66 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.7 | true | MSS | 2026-03-15T05:35:58.658758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430980 | REC_0007367 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.8 | 64 | female | 0 | 6 | 5.2 | 9 | sotorasib 960 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.658994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182919 | REC_0007368 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 8.1 | 79 | female | 1 | 39 | 5 | 7 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:35:58.659227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404659 | REC_0007369 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 8.2 | 71 | male | 0 | 7 | 6.7 | 8 | entrectinib 600 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.659458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615584 | REC_0007370 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.9 | 60 | male | 1 | 11 | 4.3 | 5 | alectinib 600 mg BID | 15.2 | false | MSI-H | 2026-03-15T05:35:58.659695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989534 | REC_0007371 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 13.2 | 68 | female | 1 | 13 | 6 | 2 | entrectinib 600 mg daily | 20.6 | true | MSI-H | 2026-03-15T05:35:58.659932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639777 | REC_0007372 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 10.5 | 72 | female | 3 | 15 | 3.5 | 1 | entrectinib 600 mg daily | 18.3 | true | MSI-H | 2026-03-15T05:35:58.660232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288848 | REC_0007373 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 11.8 | 66 | female | 1 | 14 | 4.5 | 4 | sotorasib 960 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:58.660472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611871 | REC_0007374 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 9.2 | 65 | male | 1 | 19 | 5 | 1 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:35:58.660706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773925 | REC_0007375 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 20 | 67 | male | 1 | 13 | 5.7 | 6 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:58.660945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801343 | REC_0007376 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.8 | 71 | female | 3 | 23 | 6.2 | 5 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:58.661176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470717 | REC_0007377 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.3 | 69 | female | 1 | 41 | 6.8 | 1 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:35:58.661404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998259 | REC_0007378 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.8 | 62 | female | 1 | 19 | 5 | 1 | alectinib 600 mg BID | 13.2 | true | MSI-H | 2026-03-15T05:35:58.661640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144025 | REC_0007379 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.9 | 63 | male | 0 | 20 | 4.1 | 6 | osimertinib 80 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:58.661877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914333 | REC_0007380 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 21 | 5.4 | 62 | female | 1 | 54 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 20.4 | false | MSS | 2026-03-15T05:35:58.662107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351116 | REC_0007381 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6 | 76 | female | 2 | 43 | 3.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.1 | false | MSS | 2026-03-15T05:35:58.662340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823276 | REC_0007382 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13.9 | 68 | female | 0 | 14 | 5.5 | 2 | sotorasib 960 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:58.662570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956284 | REC_0007383 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10 | 70 | female | 3 | 12 | 6.2 | 4 | alectinib 600 mg BID | 8.2 | false | MSI-H | 2026-03-15T05:35:58.662805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485391 | REC_0007384 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.6 | 71 | female | 3 | 48 | 8.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:58.663032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984600 | REC_0007385 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.6 | 53 | female | 0 | 13 | 5.1 | 5 | sotorasib 960 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:58.663313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399545 | REC_0007386 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 15 | 59 | female | 1 | 16 | 6 | 5 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:58.663551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318068 | REC_0007387 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 7.7 | 60 | female | 0 | 42 | 4.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:58.663782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313452 | REC_0007388 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 12.6 | 46 | female | 0 | 15 | 5.7 | 1 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:58.664016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463115 | REC_0007389 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 11.8 | 68 | female | 0 | 10 | 6.2 | 1 | entrectinib 600 mg daily | 26.9 | true | MSI-H | 2026-03-15T05:35:58.664314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849264 | REC_0007390 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 11.8 | 78 | male | 0 | 17 | 4 | 0 | osimertinib 80 mg daily | 23.2 | false | MSS | 2026-03-15T05:35:58.664555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194926 | REC_0007391 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.3 | 62 | male | 1 | 14 | 5.3 | 2 | sotorasib 960 mg daily | 5 | false | MSI-H | 2026-03-15T05:35:58.664791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991833 | REC_0007392 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 6.2 | 82 | female | 1 | 12 | 7.1 | 1 | pembrolizumab 200 mg q3w | 23.7 | true | MSS | 2026-03-15T05:35:58.665019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221027 | REC_0007393 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.5 | 71 | female | 1 | 25 | 7.5 | 6 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:35:58.665247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539120 | REC_0007394 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.6 | 84 | female | 2 | 16 | 3.1 | 2 | osimertinib 80 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:35:58.665478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980502 | REC_0007395 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 11.8 | 71 | female | 2 | 5 | 5.9 | 1 | osimertinib 80 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:58.665710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203402 | REC_0007396 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14 | 73 | female | 2 | 17 | 6.1 | 1 | alectinib 600 mg BID | 8.3 | true | MSI-H | 2026-03-15T05:35:58.665940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710260 | REC_0007397 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 7.9 | 74 | female | 2 | 20 | 5.3 | 8 | sotorasib 960 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:58.666165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515890 | REC_0007398 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.4 | 63 | male | 0 | 58 | 4.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 6 | false | MSS | 2026-03-15T05:35:58.666442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189248 | REC_0007399 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 8.1 | 65 | male | 1 | 10 | 4.2 | 1 | pembrolizumab 200 mg q3w | 4.1 | true | MSS | 2026-03-15T05:35:58.666677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263689 | REC_0007400 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13.3 | 73 | female | 2 | 9 | 7.1 | 1 | osimertinib 80 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:58.666907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.